Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012;17(12):1515-33.
doi: 10.1634/theoncologist.2012-0139. Epub 2012 Sep 28.

Diagnosis, treatment, and follow-up of borderline ovarian tumors

Affiliations
Review

Diagnosis, treatment, and follow-up of borderline ovarian tumors

Daniela Fischerova et al. Oncologist. 2012.

Abstract

Borderline ovarian tumors represent a heterogeneous group of noninvasive tumors of uncertain malignant potential with characteristic histology. They occur in younger women, are present at an early stage, and have a favorable prognosis, but symptomatic recurrence and death may be found as long as 20 years after therapy in some patients. The molecular changes in borderline ovarian tumors indicate linkage of this disease to type I ovarian tumors (low-grade ovarian carcinomas). The pathological stage of disease and subclassification of extraovarian disease into invasive and noninvasive implants, together with the presence of postoperative macroscopic residual disease, appear to be the major predictor of recurrence and survival. However, it should be emphasized that the most important negative prognostic factor for recurrence is just the use of conservative surgery, but without any impact on patient survival because most recurrent diseases are of the borderline type-easily curable and with an excellent prognosis. Borderline tumors are difficult masses to correctly preoperatively diagnose using imaging methods because their macroscopic features may overlap with invasive and benign ovarian tumors. Over the past several decades, surgical therapy has shifted from a radical approach to more conservative treatment; however, oncologic safety must always be balanced. Follow-up is essential using routine ultrasound imaging, with special attention paid to the remaining ovary in conservatively treated patients. Current literature on this topic leads to a number of controversies that will be discussed thoroughly in this article, with the aim to provide recommendations for the clinical management of these patients.

PubMed Disclaimer

Conflict of interest statement

Disclosures: The authors indicated no financial relationships.

Section Editors: Dennis Chi: None; Peter Harper: Sanofi, Roche, Imclone, Pfizer, GlaxoSmithKline, Lilly, Genentech (C/A); Lilly, Novartis, Sanofi, and Roche (H)

Reviewer “A”: None

Reviewer “B”: Intuitive Surgical (C/A); Vermillion, Intuitive Surgical (H)

Figures

Figure 1.
Figure 1.
Serous borderline tumor (transvaginal scan). Multilocular-solid tumor with papillae, rather smooth inner cyst wall, and regular septa and anechoic intracystic fluid.
Figure 2.
Figure 2.
Mucinous borderline tumor of endocervical type (transvaginal scan). Multilocular-solid tumor with larger number of endophytic and exophytic tumor papillae, high intrapapillary flow density, and intracystic fluid with low-level echogenicity.
Figure 3.
Figure 3.
Mucinous borderline tumor of intestinal type (transabdominal scan). Large, multilocular tumor with “honeycomb” nodule on the posterior inner wall and intracystic fluid of low-level echogenicity.
Figure 4.
Figure 4.
Exophytic implants on the surface of contralateral ovary (transabdominal scan). Hyperechogenic implants surround the contralateral ovary without involvement of ovarian stroma.

References

    1. Sutton GP. Ovarian tumors of low malignant potential. In: Rubin SC, Sutton GP, editors. Ovarian Cancer. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2001. pp. 399–417.
    1. Katsube Y, Berg JW, Silverberg SG. Epidemiologic pathology of ovarian tumors: A histopathologic review of primary ovarian neoplasms diagnosed in the Denver Standard Metropolitan Statistical Area, 1 July-31 December 1969 and 1 July-31 December 1979. Int J Gynecol Pathol. 1982;1:3–16. - PubMed
    1. Skirnisdottir I, Garmo H, Wilander E, et al. Borderline ovarian tumors in Sweden 1960–2005: Trends in incidence and age at diagnosis compared to ovarian cancer. Int J Cancer. 2008;123:1897–1901. - PubMed
    1. Sherman ME, Berman J, Birrer MJ, et al. Current challenges and opportunities for research on borderline ovarian tumors. Hum Pathol. 2004;35:961–970. - PubMed
    1. Bjorge T, Engeland A, Hansen S, et al. Trends in the incidence of ovarian cancer and borderline tumours in Norway, 1954–1993. Int J Cancer. 1997;71:780–786. - PubMed

Publication types